Your browser doesn't support javascript.
loading
Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity.
Leung, Daniel; Mu, Xiaofeng; Duque, Jaime S Rosa; Cheng, Samuel M S; Wang, Manni; Zhang, Wenyue; Zhang, Yanmei; Tam, Issan Y S; Lee, Toby S S; Lam, Jennifer H Y; Chan, Sau Man; Cheang, Cheuk Hei; Chung, Yuet; Wong, Howard H W; Lee, Amos M T; Li, Wing Yan; Chaothai, Sara; Tsang, Leo C H; Chua, Gilbert T; Cheong, Kai-Ning; Au, Elaine Y L; Kwok, Janette S Y; Chan, Koon Wing; Chong, Patrick C Y; Lee, Pamela P W; Ho, Marco H K; Lee, Tsz Leung; Tu, Wenwei; Peiris, Malik; Lau, Yu Lung.
Affiliation
  • Leung D; Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
  • Mu X; Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
  • Duque JSR; Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
  • Cheng SMS; School of Public Health, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
  • Wang M; Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
  • Zhang W; Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
  • Zhang Y; Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
  • Tam IYS; Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
  • Lee TSS; Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
  • Lam JHY; Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
  • Chan SM; Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
  • Cheang CH; Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
  • Chung Y; Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
  • Wong HHW; Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
  • Lee AMT; Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
  • Li WY; Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
  • Chaothai S; School of Public Health, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
  • Tsang LCH; School of Public Health, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
  • Chua GT; Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
  • Cheong KN; Hong Kong Children's Hospital, Hong Kong, Hong Kong SAR, China.
  • Au EYL; Division of Clinical Immunology, Department of Pathology, Queen Mary Hospital, Hong Kong, Hong Kong SAR, China.
  • Kwok JSY; Division of Transplantation and Immunogenetics, Department of Pathology, Queen Mary Hospital, Hong Kong, Hong Kong SAR, China.
  • Chan KW; Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
  • Chong PCY; Virtus Medical, Hong Kong, Hong Kong SAR, China.
  • Lee PPW; Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
  • Ho MHK; Virtus Medical, Hong Kong, Hong Kong SAR, China.
  • Lee TL; Hong Kong Children's Hospital, Hong Kong, Hong Kong SAR, China.
  • Tu W; Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
  • Peiris M; School of Public Health, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.
  • Lau YL; Centre for Immunology and Infection C2i, Hong Kong, Hong Kong SAR, China.
Front Immunol ; 13: 982155, 2022.
Article in En | MEDLINE | ID: mdl-36203563
Our study (NCT04800133) aimed to determine the safety and immunogenicity in patients with IEIs receiving a 3-dose primary series of mRNA vaccine BNT162b2 (age 12+) or inactivated whole-virion vaccine CoronaVac (age 3+) in Hong Kong, including Omicron BA.1 neutralization, in a nonrandomized manner. Intradermal vaccination was also studied. Thirty-nine patients were vaccinated, including 16 with homologous intramuscular 0.3ml BNT162b2 and 17 with homologous intramuscular 0.5ml CoronaVac. Two patients received 3 doses of intradermal 0.5ml CoronaVac, and 4 patients received 2 doses of intramuscular BNT162b2 and the third dose with intradermal BNT162b2. No safety concerns were identified. Inadequate S-RBD IgG and surrogate virus neutralization responses were found after 2 doses in patients with humoral immunodeficiencies and especially so against BA.1. Dose 3 of either vaccine increased S-RBD IgG response. T cell responses against SARS-CoV-2 antigens were detected in vaccinated IEI patients by intracellular cytokine staining on flow cytometry. Intradermal third dose vaccine led to high antibody response in 4 patients. The primary vaccination series of BNT162b2 and CoronaVac in adults and children with IEIs should include 3 doses for optimal immunogenicity.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 / BNT162 Vaccine Limits: Adult / Child / Child, preschool / Humans Language: En Journal: Front Immunol Year: 2022 Document type: Article Affiliation country: China Country of publication: Switzerland

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 / BNT162 Vaccine Limits: Adult / Child / Child, preschool / Humans Language: En Journal: Front Immunol Year: 2022 Document type: Article Affiliation country: China Country of publication: Switzerland